{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:29:50Z","timestamp":1787030990555,"version":"build-2736575974"},"reference-count":30,"publisher":"Knowledge E DMCC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Ophthalmic Vis Res"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/jovr.jovr_85_17","type":"journal-article","created":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T07:34:07Z","timestamp":1523345647000},"page":"119","source":"Crossref","is-referenced-by-count":11,"title":["Topical olopatadine hydrochloride versus ketotifen fumarate for allergic conjunctivitis"],"prefix":"10.18502","volume":"13","author":[{"given":"N","family":"Sarala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmistha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NarendraPanduranga","family":"Datti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7770","reference":[{"key":"key-10.4103\/2008-322X.229661-1","first-page":"195","volume-title":"Epidemiological profile and pharmacological management of allergic conjunctivitis: A study in Ghana","author":"Abokyi","year":"2012","journal-title":"Int J Pharm Biomed Res"},{"key":"key-10.4103\/2008-322X.229661-2","first-page":"525","volume-title":"Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops","author":"Uchio","year":"2008","journal-title":"Clin Opthalmol"},{"key":"key-10.4103\/2008-322X.229661-3","doi-asserted-by":"crossref","unstructured":"Epstein AB, Hoven PTV, Kaufman A, Carr WW. Management of allergic conjunctivitis: An evaluation of perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. Clin Ophthalmol 2009;3:329-336.","DOI":"10.2147\/OPTH.S5223"},{"key":"key-10.4103\/2008-322X.229661-4","first-page":"1","volume-title":"Allergic Conjunctivitis","author":"Sanchez","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"key":"key-10.4103\/2008-322X.229661-5","first-page":"429","volume-title":"Immunopathogenesis of ocular allergy: A schematic approach to different clinical entities","author":"Leonardi","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"key-10.4103\/2008-322X.229661-6","first-page":"129","volume-title":"Allergic Diseases of the Eye","author":"Bielory","year":"2006","journal-title":"Med Clin N Am"},{"key":"key-10.4103\/2008-322X.229661-7","first-page":"260","volume-title":"The management of allergic eye disease in primary care","author":"Chigbu","year":"2009","journal-title":"Contact Lens and Anterior Eye"},{"key":"key-10.4103\/2008-322X.229661-8","first-page":"1206","volume-title":"Efficacy and safety of ketotifen eye drops in the treatment of allergic conjunctivitis","author":"Kidd","year":"2003","journal-title":"Br J Opthalmol"},{"key":"key-10.4103\/2008-322X.229661-9","first-page":"77","volume-title":"Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis","author":"Juniper","year":"1991","journal-title":"Clin Exp Allergy"},{"key":"key-10.4103\/2008-322X.229661-10","first-page":"463","volume-title":"Executive summary of joint task force practice parameters on diagnosis and management of rhinitis","author":"Dykewicz","year":"1998","journal-title":"Ann Allergy Asthma Immunol"},{"key":"key-10.4103\/2008-322X.229661-11","first-page":"108","volume-title":"Ocular allergy pacific in the Asia Pacific region","author":"Katelaris","year":"2011","journal-title":"Asia Pacific Allergy"},{"key":"key-10.4103\/2008-322X.229661-12","first-page":"195","volume-title":"Epidemiological profile and pharmacological management of allergic conjunctivitis: A study in Ghana","author":"Abokyi","year":"2012","journal-title":"Int J Pharm Biomed Res"},{"key":"key-10.4103\/2008-322X.229661-13","first-page":"17","volume-title":"The influence of climatic and socioeconomic factors on the occurrence of allergic conjunctivitis amongst Primary school pupils in owerri urban, Nigeria","author":"Ahuama","year":"2005","journal-title":"JNOA"},{"key":"key-10.4103\/2008-322X.229661-14","first-page":"141","volume-title":"Nonseasonal allergic conjunctivitis in the tropics: Experience in a tertiary care institution","author":"Choi","year":"2008","journal-title":"Ocul Immunol Inflamm"},{"key":"key-10.4103\/2008-322X.229661-15","first-page":"312","volume-title":"Epidemiological and clinical features of allergic conjunctivitis in a reference center","author":"Marback","year":"2007","journal-title":"Arq Bras Oftalmol"},{"key":"key-10.4103\/2008-322X.229661-16","first-page":"123","volume-title":"Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three","author":"Khaled","year":"2009","journal-title":"Allergy"},{"key":"key-10.4103\/2008-322X.229661-17","first-page":"1741","volume-title":"First Hungarian report of olopatadine eye drop therapy in children and adults suffering from seasonal allergic conjunctivitis","author":"Endre","year":"2006","journal-title":"Orv Hetil"},{"key":"key-10.4103\/2008-322X.229661-18","doi-asserted-by":"crossref","unstructured":"Abelson MB, Spangler DL, Epstein AB, Mah FS, Crampton HJ. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Curr Eye Res 2007;32:1017-1022.","DOI":"10.1080\/02713680701736558"},{"key":"key-10.4103\/2008-322X.229661-19","first-page":"151;698","volume-title":"Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis","author":"Shimura","year":"2011","journal-title":"AJO"},{"key":"key-10.4103\/2008-322X.229661-20","first-page":"136","volume-title":"A comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and sodium chromoglycate ophthalmic solution in the treatment of allergic conjunctivitis","author":"Aima","year":"2009","journal-title":"J Dhaka Med Coll"},{"key":"key-10.4103\/2008-322X.229661-21","doi-asserted-by":"crossref","unstructured":"Yaylali V, Demirlenk I, Tatlipinar S, Ozbay D, Esme A, Yildirim C, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand 2003;81:378-382.","DOI":"10.1034\/j.1600-0420.2003.00079.x"},{"key":"key-10.4103\/2008-322X.229661-22","first-page":"1561","volume-title":"A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis","author":"Kateluris","year":"2002","journal-title":"Clin Ther"},{"key":"key-10.4103\/2008-322X.229661-23","first-page":"362","volume-title":"Ketotifen fumarate (Zaditen) eye drops in the treatment of seasonal allergic conjunctivitis","author":"Haicl","year":"2004","journal-title":"Cesk Slov Oftalmol"},{"key":"key-10.4103\/2008-322X.229661-24","first-page":"1206","volume-title":"Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis","author":"Kidd","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/2008-322X.229661-25","doi-asserted-by":"crossref","unstructured":"Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand 2000;78:52-55.","DOI":"10.1034\/j.1600-0420.2000.078s230052.x"},{"key":"key-10.4103\/2008-322X.229661-26","doi-asserted-by":"crossref","unstructured":"Sarker SJ, Chowdhury AN, Hussain Z, Hossain AKMM, Chowdhury H. Comparison of the therapeutic efficacy of 0.1% olopatadine hydrochloride and 0.025% ketotifen fumarate in allergic conjunctivitis. Therapy 2011;8:545-553.","DOI":"10.2217\/thy.11.48"},{"key":"key-10.4103\/2008-322X.229661-27","first-page":"399","volume-title":"Comparison of olopatadin and ketotifen in the treatment of allergic conjunctivitis","author":"Rodr\u00edguez","year":"2009","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"key-10.4103\/2008-322X.229661-28","first-page":"1221","volume-title":"Perception and Quality of Life Associated With the Use of Olopatadine 0.2%(Pataday) in Patients With Active Allergic Conjunctivitis","author":"Scoper","year":"2007","journal-title":"Adv Ther"},{"key":"key-10.4103\/2008-322X.229661-29","doi-asserted-by":"crossref","unstructured":"Artal MN, Luna JD, Discepola M. A forced choice comfort of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%. Acta Ophthalmol Scand Suppl 2000;230:64-65.","DOI":"10.1034\/j.1600-0420.2000.078s230064.x"},{"key":"key-10.4103\/2008-322X.229661-30","first-page":"16","volume-title":"Adverse drug monitoring study of azelastine, epinastine, ketotifen and olopatadine ophthalmic solution in patients diagnosed with seasonal and perennial allergic conjunctivitis","author":"Jain","year":"2012","journal-title":"AJPSR"}],"container-title":["Journal of Ophthalmic and Vision Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T10:03:35Z","timestamp":1734429815000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jovr.org\/text.asp?2018\/13\/2\/119\/229661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"alternative-id":["229661"],"URL":"https:\/\/doi.org\/10.4103\/jovr.jovr_85_17","relation":{},"ISSN":["2008-322X"],"issn-type":[{"value":"2008-322X","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}